IPO11

Across TCGA pan-cancer cohorts, IPO11 mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated IPO11 data layer compared with 23 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher IPO11 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated IPO11 expression acts as an unfavorable survival marker, although some lineages such as HNSC and LSCC show a favorable association.

PDAC, CCRCC, and COAD are the cancer types where IPO11 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	OS	Tertile	All	0.382	0.682	<.001	62	view →
CCRCC	DFS	Tertile	III,IV	0.327	0.696	.002	22	view →
COAD	DFS	Tertile	All	0.917	1.000	.031	12	view →
LUAD	DFS	Median	III,IV	0.409	0.941	.010	5	view →
HNSC	OS	Quartile	IV	0.957	0.590	.005	4	view →
LSCC	DFS	Median	II,III,IV	0.888	0.676	.018	3	view →
GBM	OS	Median	All	0.635	0.441	.037	1	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

IPO11–PDAC (OS)

Open the PDAC breakdown →